Mumbai, May 29, 2025: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2025. The Board of Directors took record of these results at its meeting held in Mumbai today.
Key highlights of Q4FY25 financial performance
• Total Revenue from Operations was ₹ 31,438 million, with YoY growth of 7.1%.
o India sales were ₹ 21,355 million, YoY growth of 8.1%.
o International sales were ₹ 9,747 million, with YoY growth of 7.2%.
• Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were ₹ 3,913 million, resulting in an EBITDA margin of 12.4% vs. 13.7% in Q4FY24. EBITDA declined by 2.7% YoY.
• R&D expenses for Q4FY25 were ₹ 1,585 million, or 5.0% of total revenue from operations, compared to ₹ 1,757 million in Q4FY24 at 6.0% of total revenue from operations.
• Profit before tax before exceptional items was ₹ 3,963 million, YoY growth of 4.3%.
• Net Profit (after Minority Interest) was ₹ 3,059 million, YoY growth of 4.2%.
• According to IQVIA (SSA) data, for Q4FY25:
o The Company ed a growth of 6.5% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 6.9%.
o The acute segment growth outperformed IPM by 150 bps at 7.5%. Key highlights of FY25 financial performance
• Total Revenue from Operations was ₹ 129,645 million, with YoY growth of 2.3%.
o India sales were ₹ 89,837 million, with YoY growth of 6.5%.
o International sales were ₹ 38,210 million, with YoY de-growth of 4.5%.
• Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were ₹ 25,122 million, resulting in an EBITDA margin of 19.4% vs. 17.7% in FY24. EBITDA increased by 11.9% YoY.
• R&D expenses for FY25 were ₹ 5,620 million, or 4.3% of total revenue from operations, compared to ₹ 5,229 million in FY24 at 4.1% of total revenue from operations.
• Profit before tax before exceptional items was ₹ 25,270 million, YoY growth of 17.8%.
• Net Profit (after Minority Interest) was ₹ 21,655 million, YoY growth of 20.6%.
• The cash and balance at the end of 31st March, 2025, is ₹46.2 billion.
• According to IQVIA (SSA) data, for FY25:
o The Company ed a growth of 6.8% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 7.7%.
o The acute segment growth has outperformed IPM in FY25 by 30 bps at 6.9%.
Commenting on the Q4 & FY25 results, Dr. Vikas Gupta, CEO of Alkem, said, “We ended the year on a good note, with healthy growth in our India business during Q4 and improved profitability and margins for the full year. Our domestic business continues to gain momentum, reinforcing our confidence in its long-term growth trajectory. This performance is driven by strong execution and targeted initiatives across our domestic operations. In the international businesses, excluding the Americas, we are seeing good traction, with several key markets making significant contributions to our growth. As we moved forward, we remain focused on strategic growth opportunities and operational excellence to drive sustainable returns.”
Operational Highlights
Domestic Business
Q4FY25 Key Highlights
• India sales were ₹ 21,355 million, YoY growth of 8.1%.
• The contribution of domestic sales to total sales in Q4FY25 was 68.7% vs. 68.5% in Q4FY24.
• According to IQVIA (SSA) data, for FY25, the company achieved a 6.5% year-overyear (YoY) growth compared to the Indian Pharmaceutical Market (IPM), which grew by 6.9%.
• During Q4FY25, we have outperformed in four therapies: Gastrointestinal grew by ~1.5X, VMN ~1.8X, Respiratory ~2.6X and Gynae ~3.8X. FY25 Key Highlights
• India sales were ₹ 89,837 million, with YoY growth of 6.5%.
• The contribution of domestic sales to total sales in FY25 was 70.2% vs. 67.8% in FY24.
• As per IQVIA (SSA) data, for FY25, the company ed a growth of 6.8% YoY vs. the Indian Pharmaceutical Market (IPM), which grew by 7.7%
• In FY25, we have outperformed six therapies: VMN grew by 1.6X; Anti-diabetic grew by ~1.1X; Gastro intestinal grew by 1.2X; Neuro/CNS grew by ~1.3X; Gynaec ~2.1X and Respiratory ~1.5X.
International Business
Q4FY25 Key Highlights
• International sales were ₹ 9,747 million, with YoY growth of 7.2%.
• Overall contribution of US sales to total sales was 19.6% in Q4FY25 vs. 21.6% in Q4FY24.
• Non-US business sales contributed 11.8% to total sales in Q4FY25 vs. 9.9% in Q4FY24.
• During the Q4FY25, the Company filed 06 abbreviated new drug applications (ANDAs) with the USFDA and received 04 ANDA approvals.
FY25 Key Highlights
• International sales were ₹ 38,210 million, with YoY de-growth of 4.5%.
• The Non-US business demonstrated healthy performance, growing by around 8.7% YoY, fuelled by robust growth in Australia and key European markets.
• Overall contribution of US sales to total sales was 19.4% in FY25 vs. 22.3% in FY24.
• Non-US business sales contributed 10.5% to total sales in FY25 vs. 9.9% in FY24.
• During the year, the Company filed 9 abbreviated new drug applications (ANDAs) with the US FDA and received 14 ANDA approvals (including 3 tentative approvals – TA).